Theravance Biopharma, Inc.
General ticker "TBPH" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $540.3M (TTM average)
Theravance Biopharma, Inc. follows the US Stock Market performance with the rate: 52.7%.
Estimated limits based on current volatility of 2.3%: low 18.67$, high 19.56$
Factors to consider:
- Total employees count: 97 (-2.0%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Lack of profitability, Declining product acceptance, Regulatory and compliance, Labor/talent shortage/retention, Partnership obligations
- Current price 39.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.77$, 13.43$]
- 2025-12-31 to 2026-12-31 estimated range: [6.74$, 13.38$]
Financial Metrics affecting the TBPH estimates:
- Negative: with PPE of -29.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.44 <= 0.33
- Positive: Investing cash flow per share per price, % of 2.60 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 49.57 <= 63.39
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.54 <= 0.79
Short-term TBPH quotes
Long-term TBPH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $51.35MM | $57.42MM | $64.38MM |
| Operating Expenses | $143.30MM | $113.46MM | $111.33MM |
| Operating Income | $-91.96MM | $-56.03MM | $-46.95MM |
| Non-Operating Income | $-0.86MM | $6.77MM | $2.33MM |
| Interest Expense | $6.37MM | $2.35MM | $2.55MM |
| R&D Expense | $63.39MM | $40.62MM | $37.64MM |
| Income(Loss) | $-92.81MM | $-49.27MM | $-44.61MM |
| Taxes | $0.01MM | $5.92MM | $11.80MM |
| Other Income(Loss) | $964.96MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-92.82MM | $-55.19MM | $-56.42MM |
| Stockholders Equity | $441.80MM | $213.00MM | $175.54MM |
| Assets | $607.40MM | $382.00MM | $354.16MM |
| Operating Cash Flow | $-186.99MM | $-27.00MM | $-11.54MM |
| Capital expenditure | $0.57MM | $2.49MM | $0.33MM |
| Investing Cash Flow | $1,154.01MM | $-32.70MM | $12.28MM |
| Financing Cash Flow | $-758.81MM | $-198.93MM | $-2.50MM |
| Earnings Per Share** | $-1.26 | $-1.00 | $-1.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.